Key terms

About KNSA

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest KNSA news

Apr 02 2:55pm ET Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Goldman Sachs by TipRanks Apr 02 7:46am ET Kiniksa announces development indication for abiprubart by TipRanks Apr 02 7:42am ET Kiniksa Pharmaceuticals Advances Clinical Trials and Ensures Positive Cash Flow by TipRanks Feb 28 12:00pm ET Analysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA) by TipRanks Feb 28 7:32am ET Kiniksa reports Q4 EPS 35c, consensus (14c) by TipRanks Jan 05 4:32am ET Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Rhythm Pharmaceuticals (RYTM) and Kiniksa Pharmaceuticals (KNSA) by TipRanks Jan 04 3:15pm ET Strong Arcalyst Sales and Promising Pipeline Reinforce Kiniksa Pharmaceuticals Buy Rating by TipRanks Jan 04 7:42am ET Kiniksa expects cash to fund operating plan into at least 2027 by TipRanks Jan 04 7:42am ET Kiniksa says abiprubart Phase 2 trial meets primary efficacy endpoint by TipRanks Jan 04 7:38am ET Kiniksa sees 2024 ARCALYST net product revenue $360M-$380M by TipRanks Jan 04 7:34am ET Kiniksa reports Q4 ARCALYST net product revenue $71.2M by TipRanks

No recent press releases are available for KNSA

KNSA Financials

1-year income & revenue

Key terms

KNSA Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

KNSA Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

People walk past the New York Stock Exchange (NYSE) on March 28, 2024 in New York City.
NDZ/STAR MAX/IPx/AP
What stalled this year’s seemingly infallible stock market rally
A working oil pumpjack is pictured in Taft, Kern County, California on September 21, 2023.
Frederic J. Brown/AFP/Getty Images
Oil prices get short-lived boost from attack on Iran
NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days